Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 1, 2014, Pages 126-131

  Jänne, Pasi A ^a   Paz Ares, Luis ^b   Oh, Yun ^c   Eschbach, Corinna ^d   Hirsh, Vera ^e   Enas, Nathan ^f   Brail, Leslie ^f   Von Pawel, Joachim ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Cancer Care Center of Frederick   (United States)

^d Asklepios Klinik Harburg   (Germany)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f ELI LILLY AND COMPANY   (United States)

^g Asklepios Klinikum Gauting   (Germany)

Author keywords

Activated receptor agonist; Chemotherapy; Cisplatin; Gemcitabine; Leukotriene receptor agonist; Lung cancer; LY293111; Peroxisome proliferators

Indexed keywords

CISPLATIN; ETALOCIB; GEMCITABINE; PLACEBO;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOMAGNESEMIA; LIVER DYSFUNCTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOATES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE B4; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84891788240     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000037     Document Type: Article

References (15)

1. Jackson WT, Froelich LL, Boyd RJ, et al. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: In vitro studies. J Pharmacol Exp Ther 1999;288:286-294
2. Sawyer JS, Bach NJ, Baker SR, et al. Synthetic and structure/activity studies on acid-substituted 2-arylphenols: Discovery of 2-[2-propyl-3-[3- [2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist. J Med Chem 1995;38:4411-4432
3. Ara G, Teicher BA. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids 1996;54:3-16
4. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A 1996;93:5241-5246
5. Budman DR, Calabro A. Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anticancer Drugs 2004;15:877-881
6. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-1138
7. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-2099
8. Bildirici I, Roh C-R, Schaiff WT, et al. The lipid droplet-associated protein adipophilin is expressed in human trophoblasts and is regulated by peroxisomal proliferator-activated receptor-γ/retinoid X receptor. J Clin Endocrinol Metab 2003;88(12):6056-6062
9. Baetz T, Eisenhauer E, Siu L, et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest New Drugs 2007;25:217-225
10. Odwyer P, Stevenson JP, Petrylak DP, et al Phase I and pharmacokinetic trial of LY293111 in combination with gemcitabine. Europ J Canc 2002; 38: S89
11. Schwartz GK, Weitzman A, Oreilly E, et al. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J Clin Oncol 2005;23:5365-5373
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
13. Gemzar [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
14. Saif MW, Oettle H, Vervenne WL, et al. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J 2009;15:339-343
15. Jänne PA, Paz-Ares Rodriguez L, Gottfried M, et al. Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma. J Clin Oncol 2006;24:18s.